VacZine AnalyticsVacZine Analytics is an established strategic research consultancy based in the United Kingdom. Its specific aim is to provide high-quality disease and commercial analysis to those working within or in collaboration with the growing vaccine/biologics industry. Through our “custom” and “off the shelf” syndicated product lines the key focus of the company is to help clients build the case for developing new vaccines. |
 |
List of reports from VacZine Analytics
|
Disease INFOPACK: Chlamydia trachomatis
5/1/2008 | published by: VacZine Analytics
... pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are “silent” and unrecognized. This is of concern due to continued transmission especially ...
|
more...
|
$4,595.00
|
|
Disease INFOPACK: Community-acquired MRSA
5/1/2008 | published by: VacZine Analytics
... severe disease in previously healthy persons with no history of contact with the hospital setting. CA-MRSA is transmitted from person-to-person with disease outbreaks being reported in competitive sportsmen, inmates and day-care attendees. This DiseaseINFOPACK report ...
|
more...
|
$4,595.00
|
|
Vaccine Intellectual Property Review
4/1/2008 | published by: VacZine Analytics
... Analytics has created a unique database (~300 patents) mapping the current vaccine intellectual property landscape pertaining to potential vaccine antigens and their commercial use in vaccines. Summary analyses of the database reveal striking differences between ...
|
more...
|
$10,995.00
|
|
Disease INFOPACK: Acinetobacter baumannii
10/1/2007 | published by: VacZine Analytics
... range between 30-75%. Of greatest concern is the high intrinsic drug resistance of the most common type Acinetobacter baumannii which forces physicians to use older drugs such as polymixins and colistin with low tolerability profiles. ...
|
more...
|
$4,595.00
|
|
Disease INFOPACK: Foot-and-mouth disease
10/1/2007 | published by: VacZine Analytics
... infected animals and spread very rapidly. The most significant feature of foot-and-mouth disease is its devastating economic impact with the cost of the 2001 UK epidemic estimated between $12-13 billion. This DiseaseINFOPACK report is an ...
|
more...
|
$4,595.00
|
|
Disease INFOPACK: ESBL-producing E.coli
10/1/2007 | published by: VacZine Analytics
... hospital settings. In rare cases ExPEC can also cause bloodstream infections which lead to sepsis and even death. Since the 1980s, hospital E.coli has become multidrug resistant through the production of extended-spectrum beta-lactamase enzymes (ESBLs). ...
|
more...
|
$4,595.00
|
